Interpace Diagnostics Announces Expanded Coverage Among Blue Cross Blue Shield Plans

14 New Plans Cover ThyGenX® and ThyraMIR® in 2018 to Date PARSIPPANY, N.J., May 10, 2018 -- (Healthcare Sales & Marketing Network) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial a... Diagnostics, Oncology, Reimbursement Interpace Diagnostics, ThyraMir, thyroid cancer, PancraGEN, pancreatic cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news